| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomics_Paediatric v0.50 | UGT1A1 |
David Metz gene: UGT1A1 was added gene: UGT1A1 was added to Pharmacogenomics_Paediatric. Sources: Other Mode of inheritance for gene: UGT1A1 was set to Other Publications for gene: UGT1A1 were set to 21412232; 25817555; 26417955 Phenotypes for gene: UGT1A1 were set to Irinotecan metabolism, increased toxicities with reduced metaboliser status; Atazanavir metabolism, increased risk jaundice and discontinuation with reduced metaboliser status Mode of pathogenicity for gene: UGT1A1 was set to Other Review for gene: UGT1A1 was set to GREEN Added comment: Sources: Other |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||